dlvr.it Promoted Storieshttps://static.dlvr.it/images/d.pnghttps://static.dlvr.it/images/favicon.icotag:news.dlvr.it,2015-03-22:/organization/675002015-03-22T13:28:10-07:00tag:news.dlvr.it,2015-03-14:3662362015-03-14T08:24:02-07:00

Data from 21,000 patient study presented at American College of Cardiology 64th Annual Scientific Session and simultaneously published in New England Journal of Medicine ]]>

tag:news.dlvr.it,2015-01-29:3411622015-01-29T09:44:02-08:00

]]>

tag:news.dlvr.it,2015-01-14:3532502015-01-14T04:01:24-08:00

BRILINTA 60mg and 90mg demonstrate statistically significant reduction in major cardiovascular thrombotic events in patients with a history of heart attack ]]>

tag:news.dlvr.it,2014-11-21:3152962014-11-21T08:08:02-08:00

$200+ Million Investment to Support Company’s Maturing Biologics Pipeline ]]>

tag:news.dlvr.it,2014-11-16:3329962014-11-16T06:00:02-08:00

]]>

tag:news.dlvr.it,2014-11-13:3144792014-11-13T04:00:40-08:00

Updates on BRILINTA (ticagrelor) tablets development program and data from cardiovascular portfolio to be presented at American Heart Association (AHA) Scientific Sessions 2014 ]]>

tag:news.dlvr.it,2014-10-30:3173462014-10-30T04:02:15-07:00

First U.S. approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release ]]>

tag:news.dlvr.it,2014-10-15:3101492014-10-15T04:30:14-07:00

]]>

tag:news.dlvr.it,2014-10-06:3068242014-10-06T04:30:14-07:00

AHA/ACC Gives Class IIa Recommendation for Use of BRILINTA® (ticagrelor) Tablets Over Clopidogrel in NSTE-ACS Patients with Early Invasive or Ischemia-guided Strategy or Receiving a Coronary Stent ]]>

tag:news.dlvr.it,2014-09-16:3008792014-09-16T10:58:02-07:00

]]>

tag:news.dlvr.it,2014-09-08:2974662014-09-08T04:00:52-07:00

]]>

tag:news.dlvr.it,2014-08-19:2922922014-08-19T04:00:49-07:00

]]>

tag:news.dlvr.it,2014-06-26:2771672014-06-26T06:21:05-07:00

]]>

tag:news.dlvr.it,2014-06-03:2695602014-06-03T07:30:26-07:00

]]>

tag:news.dlvr.it,2014-05-06:2596822014-05-06T06:11:15-07:00

]]>